In Q2 2026, ClearPoint Neuro continued to generate revenue from its core neurosurgery navigation hardware and disposable components but faced significant net losses attributable to the capital-intensive build-out of a new preclinical CRO facility. This strategic pivot into providing GLP-compliant services to biopharma adds a new growth avenue but also heightens fixed costs and regulatory complexity. The company’s sales model balances upfront capital equipment installations with recurring disposable product revenue, a dynamic common among medical device firms, while incrementally expanding into facility-based contracted research services. Success hinges on scaling the CRO without compromising regulatory compliance or customer demand assumptions. ClearPoint maintains strong liquidity yet carries meaningful net debt, underscoring the financial strain of its expansion.